| (18F)-FDG PET/CT | 548 |
| (68)Ga-PSMA PET/CT | 647 |
| 3-D | 713 |
| Abdomen | 414 |
| Abdominal aorta | 414 |
| Abdominal aortic aneurysm | 331 |
| Ablation | 167, 318, 628, 800 |
| Abscess | 309 |
| Absolute ethanol | 621 |
| Active extravasation | 632 |
| Adrenal | 640 |
| Adrenal adenoma | 234 |
| Adrenal glands | 234 |
| Adrenal mass | 234 |
| Advanced filter retrieval | 500, 638 |
| Advanced modeled iterative | |
| reconstruction | 268 |
| Advanced prostate cancer | 29 |
| Air embolism | 478 |
| Albumin-to-globulin ratio | 520 |
| Aldosteronism | 640 |
| Alveolar echinococcosis | 736 |
| Aneurysm | 68, 350 |
| Angiocardiography | 138 |
| Angiogenesis | 704 |
| Angiography | 713, 819 |
| Angiomyolipoma | 170 |
| Anthropomorphic phantom | 555 |
| Anticoagulant therapy | 733 |
| Arteriosclerosis | 414 |
| Artery | 713 |
| Artifact | 175, 719 |
| Artificial intelligence | 40, 260, 460 |
| Atherosclerosis | 175 |
| Autologous | 596 |
| Axillary artery | 117 |
| Axillary lymph node metastasis | 469 |
| B3 lesions | 579 |
| Balloon anchor technique | 161 |
| Balloon angioplasty | 535 |
| Balloon-occluded transcatheter arterial chemoembolization | 161 |
| Benign | 183 |
| Benign endometrium lesions | 183 |
| BI-RADS category | 469 |
| Biliary stent | 509 |
| Biliary system | 367 |
| Biopsy | 800 |
| Bladder | 412 |
| Bone | 190 |
| Bowel | 24 |
| Brain | 664 |
| Breast | 260, 761 |
| Breast cancer | 53, 244, 251, 469, 579, 588 |
| Budd-Chiari syndrome | 428 |
| Cancer | 109, 205, 260, 412 |
| Cancer-specific survival | 520 |
| Cardiac | 268 |
| Cardiac catheterization | 68 |
| Cardiac function | 548 |
| Cardiac magnetic resonance | 682 |
| Cardiac magnetic resonance imaging | 276 |
| Cardiology | 202 |
| Cardiopulmonary resuscitation | 548 |
| Catheter | 138, 309, 367 |
| Catheter angiography | 138, 331 |
| Celiac trunk morphology | 161 |
| Cellular fibroadenoma | 674 |
| Chest phantom | 691 |
| Chronic allograft damage index | 212 |
| Chronic total occlusion | 492 |
| Chyle leak | 326 |
| Cine MRU | 1 |
| Cirrhosis | 146, 410 |
| Combination therapy | 805 |
| Combine | 342 |
| Combined therapy | 805 |
| Common hepatic artery insertion | 161 |
| Comparative study | 805 |
| Complex fibroadenoma | 674 |
| Complex filter retrieval | 500 |
| Complicated fibroadenoma | 674 |
| Complications | 318 |
| Computed tomography | 18, 80, 109, 117, 155, 228, 234, 283, 379, 390, 402, 414, 561, 563, 596 |
| Computed tomography | |
| angiography | 68, 175, 268 |
| Cone-beam computed tomography | 713 |
| Cone-beam CT | 832 |
| Congenital | 410 |
| Congenital heart disease | 68 |
| Contrast | 640 |
| Contrast agents | 244 |
| Contrast enhanced ultrasound | 469 |
| Contrast enhancement | 228 |
| Contrast-enhanced spectral | |
| mammography | 244 |
| Contrast-enhanced ultrasound | 632 |
| Conventional | 251 |
| Conventional scoring balloon | 535 |
| Conventional ultrasound | 469 |
| Core needle biopsy | 579 |
| Coronary artery | 202 |
| Coronary artery disease | 68, 202 |
| COVID-19 | 53, 91, 103, 414, 563 |
| COVID-19 pandemic | 373 |
| Crohn’s disease | 24, 437 |
| Cryoablation | 167 |
| Cryoneurolysis | 614 |
| Cryotherapy | 800 |
| CT | 24, 291, 309, 373, 640, 800 |
| CT angiography | 202, 331 |
| CT-guided PTNB | 478 |
| Cutting balloon | 535 |
| DECT | 103, 736 |
| Deep learning | 40, 437 |
| Deep learning reconstruction | 664 |
| Deep neural network | 588 |
| Deep vein thrombosis | 638, 733 |
| Diagnosis | 68, 190, 202, 410, 561 |
| Diffusion | 664 |
| Diffusion weighted imaging | 428 |
| Diverticulum | 68 |
| DLP | 736 |
| Dobhoff tube | 710 |
| Doppler ultrasound | 212 |
| Dose reduction strategies | 268 |
| Double-J stent | 312 |
| Drug-coated balloon | 535 |
| Dual-energy computed tomography | 276 |
| Echo-planar imaging | 786 |
| Echocardiogram | 68 |
| Economic evaluation | 492 |
| Embolectomy | 794 |
| Embolism | 68 |
| Embolization | 170, 326, 331, 542 |
| Emergency | 300 |
| Emergency radiology | 117 |
| Endoleak | 331 |
| Endometrial cancer | 183 |
| Endovascular treatment | 535 |
| Enteer® | 492 |
| Entrance surface dose | 555 |
| Entropy | 682 |
| Epilepsy | 396 |
| ethanol | 170, 342 |
| Femoro- popliteal | 492 |
| Femoropopliteal lesions | 535 |
| Field of view | 555 |
| Filter | 638 |
| Flouroscopy | 710 |
| Flow diverter | 350 |
| Fluoroscopy | 309, 813 |
| Foam sclerotherapy | 826 |
| Follicular phase | 656 |
| Follow-up | 103 |
| Fragility index | 529 |
| FRED | 350 |
| Gallbladder | 367 |
| Gastric cancer | 228 |
| Gastric varices | 146 |
| Gastrojejunostomy | 710 |
| Gastropexy | 813 |
| Gastrostomy | 813 |
| Genicular artery embolization | 614 |
| Glucose metabolism | 548 |
| Goiter | 628 |
| HCC | 609 |
| Hematoma | 632 |
| Hemoptysis | 713, 819 |
| Hemorrhage | 155 |
| Hemothorax | 819 |
| Hepatic | 563 |
| Hepatic arterial infusion chemotherapy | 832 |
| Hepatic tumors | 318 |
| Hepatocellular carcinoma | 342, 359, 450, 520, 704, 741, 805, 832 |
| High resolution diffusion weighted | 251 |
| High risk lesion of breast | 260 |
| High-intensity focused ultrasound (HIFU) | 195 |
| High-resolution | 291 |
| Histopathology | 59 |
| Human papillomavirus DNA tests | 460 |
| Image guided breast biopsy | 579 |
| Image quality | 437, 786 |
| Image-guided biopsy | 260 |
| Immunotherapy | 80 |
| Improvement | 300 |
| In vivo rat model | 621 |
| Inferior vena cava | 638 |
| Inferior vena cava filter | 638, 733 |
| Inflammatory bowel disease | 24 |
| Intermittent pneumatic venous compression devices | 326 |
| Interreader agreement | 29 |
| Interventional | 128, 138, 529, 628, 713, 719, 813 |
| Intraoperative radiotherapy | 761 |
| Intravoxel incoherent motion | 664 |
| Intravoxel incoherent motion diffusion-weighted imaging | 656 |
| Intravoxel incoherent motion imaging | 786 |
| Invasive | 412 |
| Invisible tumor | 609 |
| Iodine-125 seed | 509 |
| IVC filter retrieval | 638 |
| Kidney | 170, 212 |
| Knee pain | 614 |
| Left ventricular non-compaction | 682 |
| Lesion-liver CNR | 128 |
| Liver | 410, 805 |
| Liver Imaging Reporting and Data System | 741 |
| Liver metastases | 571, 609 |
| Liver regeneration | 621 |
| Liver SNR | 128 |
| Liver tumor burden | 571 |
| Localization | 155 |
| Low-dose | 291 |
| Low-dose computed tomography | 691 |
| LR-M | 741 |
| Lung | 80, 103, 291, 561, 794 |
| Lung adenocarcinoma | 379 |
| Lung cancer | 283 |
| Luteal phase | 656 |
| Lymph node metastasis | 228 |
| Lymphangiogram | 326 |
| Lymphangiography | 542 |
| Lymphatic | 542 |
| Lymphocele | 542 |
| Machine learning | 40, 460 |
| Magnetic resonance imaging | 1, 18, 59, 68, 195, 219, 251, 276, 390, 396, 412, 664, 741, 753, 786 |
| Major adverse cardiovascular events | 682 |
| Male urethra | 9 |
| Malignancy | 800 |
| Malignant biliary obstruction | 509 |
| Malignant cerebral edema | 402 |
| Malignant ureteral obstruction | 312 |
| Mammography | 53, 59, 588, 761 |
| MCA | 350 |
| MDCT | 205 |
| Menses phase | 656 |
| Menstrual cycle | 656 |
| Meta-analysis | 478, 509 |
| Metaplastic breast cancer | 59 |
| Metastasis | 167 |
| METastasis Reporting and Data System for Prostate Cancer | 29 |
| Metastatic tumor | 190 |
| Microwave ablation | 318, 359 |
| Middle cerebral artery | 402 |
| Model | 741 |
| mpMRI | 29 |
| MR elastography | 428 |
| MR enterography | 24, 437 |
| MRI | 128, 183 |
| MSK | 719 |
| Musculoskeletal | 719 |
| Myeloma | 596 |
| Myocardial energy metabolism | 548 |
| Myocarditis | 276 |
| N-butyl-cyanoacrylate | 621 |
| Neoadjuvant chemoradiotherapy | 219 |
| Neoplasm | 561 |
| Neoplasm staging | 219 |
| Neoplasm-stage | 753 |
| Nodule | 561, 628 |
| Noise reduction | 437 |
| Nomogram | 283, 379, 771 |
| Non-small cell lung cancer | 771 |
| Non-surgical management | 309 |
| OffRoad® | 492 |
| Olfactory bulb | 396 |
| Olfactory sulcus | 396 |
| Olfactory tract | 396 |
| Oncology | 205 |
| Oral cancer | 786 |
| Osteoarthritis | 614 |
| Osteochondroma | 390 |
| Osteochondromatosis | 390 |
| Outback® | 492 |
| Outpouching | 68 |
| Ovarian dysgerminoma | 18 |
| Overall survival | 520 |
| Pancreas | 167, 563 |
| Percutaneous | 367 |
| Percutaneous endovascular variceal embolization | 826 |
| Percutaneous thrombin injection | 632 |
| Percutaneous transthoracic needle | |
| biopsy | 819 |
| Perfusion deficit | 103 |
| Pericardial | 68 |
| Peripheral arterial disease | 175 |
| Peripheral artery disease | 535 |
| Photon-counting | 291 |
| Pipeline | 350 |
| Pneumonia | 373 |
| Pneumonitis | 80 |
| Pneumothorax | 155 |
| Polyvinyl alcohol | 170 |
| Portal hypertension | 410, 826 |
| Portal vein | 410 |
| Portal vein embolization | 621 |
| Positron emission tomography | 379 |
| Practice | 300 |
| Prediction | 91, 771 |
| Primary treatment | 359 |
| Prognosis | 91, 450, 682 |
| Prostate neoplasms | 753 |
| Prostate perfusion MRI | 647 |
| Prostate zones | 753 |
| PSA | 647 |
| PSA density | 647 |
| Pseudoaneurysm | 68 |
| Pseudocirrhosis | 571 |
| Pulmonary | 155, 794 |
| Pulmonary embolism | 500, 794 |
| Pulmonary nodule | 691 |
| Pulmonary toxicity | 80 |
| Quantitative parameters | 786 |
| Quantitative volumetric analysis | 450 |
| Radiation | 373, 710, 736 |
| Radiation dosage | 175 |
| Radiculomedullary artery | 713 |
| Radiofrequency ablation | 318, 342, 450, 614 |
| Radiography | 555 |
| Radiological | 771 |
| Radiology | 9, 18, 40, 205, 300, 460, 529, 713, 813 |
| Radiomic signature | 91 |
| Radiomics | 283, 402 |
| RCT | 529 |
| Re-entry device | 492 |
| Real-time sequence | 128, 719 |
| Reconstruction algorithm | 691 |
| Reconstructive surgery | 1 |
| Rectal cancer | 219 |
| Recurrent HCC | 359 |
| Renal | 205, 800 |
| Renal transplant | 212 |
| Reproducibility | 529 |
| Resin microspheres | 704 |
| Response assessment category | 29 |
| Retrograde exchange | 312 |
| Risk factor | 478 |
| Sacroiliac joint | 390 |
| Sacrum injury | 195 |
| Sarcopenia | 596 |
| Scintigraphy | 190 |
| Sclerotherapy | 542 |
| Screening interruption | 53 |
| Secondary treatment | 359 |
| Selective intra-arterial lipiodol injection | 609 |
| Sequence parameter | 128 |
| Shearwave elastography | 674 |
| Shielding | 555 |
| Signal intensity | 128 |
| Simple fibroadenoma | 674 |
| Single-photon emission-computed tomography | 190 |
| Solid pulmonary nodules | 283 |
| Spectral computed tomography | 691 |
| Spread through air spaces | 771 |
| Steatosis | 563 |
| Stent | 367 |
| Stent failure | 312 |
| Stomach | 813 |
| Stroke | 402 |
| Subclavian artery | 117 |
| Subintimal angioplasty | 492 |
| Submassive | 794 |
| Superb microvascular imaging | 212 |
| Superior vena cava | 638 |
| Surgery | 9 |
| Surgery delay | 53 |
| Surgical pathology | 219 |
| Survey | 46, 300 |
| Survival | 342 |
| T1 mapping | 428 |
| T2 mapping | 183, 428 |
| T2 value | 183 |
| Tandem ureteral stents | 312 |
| Teleradiology | 46 |
| Texture analysis | 234 |
| The aortic-celiac trunk angle | 161 |
| Therapeutic embolization | 713 |
| Therapy | 80 |
| Thermal ablation | 609 |
| Thoracic | 373, 596 |
| Thoracic duct | 326 |
| Three-dimensional | 68 |
| Thrombectomy | 794 |
| Thromboembolism | 500 |
| Thrombolysis | 733 |
| Thymic epithelial tumor | 109 |
| Thymoma | 109 |
| Thyroid | 167, 628 |
| Time | 710 |
| TIPS | 146 |
| Transarterial chemoembolization | 520, 805 |
| Transarterial Radioembolization | 704 |
| Transcatheter arterial embolization | 819 |
| Transplantation | 596 |
| Transvenous obliteration | 146 |
| Trauma | 117 |
| Tumor | 109, 412 |
| Tumor ablation | 805 |
| Tumor burden | 450 |
| Tumor morphology | 251 |
| Tumor perfusion | 832 |
| Tumor response | 832 |
| Tumor volume | 228, 753 |
| Turbo spin-echo | 786 |
| Turkey | 46 |
| Ultra-high-pitch computed tomography coronary angiography | 268 |
| Ultra-high-resolution | 291 |
| UltraScore balloon | 535 |
| Ultrasonography | 40, 59, 674, 761 |
| Ultrasound | 18, 309 |
| Ultrasound ablation | 195 |
| Upper GI bleeding | 146 |
| Ureter | 1 |
| Ureteric stricture | 1 |
| Urethral stenosis | 9 |
| Urethrocystography | 9 |
| Urology | 9 |
| Uterine cervical neoplasms | 460 |
| Uterine fibroids | 195 |
| Uterus | 656 |
| Vacuum assisted biopsy | 579 |
| Variceal bleeding | 826 |
| Vascular | 138 |
| Venography | 640, 733 |
| Venous thromboembolism | 500 |
| Ventricles | 68 |
| Virtual non-enhanced | 736 |
| Visceral pleural invasion | 379 |
| Visualization | 128 |
| Wash-in rate | 647 |
| Wash-out rate | 647 |
| Whole breast radiotherapy | 761 |
| Wraparound lead | 555 |
| Y-90 | 704 |